



Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement          by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
	Applicant Wong		
	Filing Date 09-25-2003	Group Art Unit 1615	

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/S.F./	AA	07/357,394					05/1989
	AB	07/386,835					07/1989
	AC	10/820,563					04/2004
	AD	60/587,092					07/2004
	AE	2004/0019098	01/2004	Andrews, et al.			
	AF	2004/0132824	07/2004	Gil, et al.			
	AG	2004/0137059	07/2004	Nivagiolli, et al.			
	AH	2004/0151753	08/2004	Chen			
	AI	2004/0170665	09/2004	Donovan			
	AJ	2004/0266776	12/2004	Gil, et al.			
	AK	2005/0048099	03/2005	Shiah, et al.			
	AL	2005/0058696	03/2005	Donello, et al.			
	AM	2005/0059664	03/2005	Gil, et al.			
	AN	2005/0059744	03/2005	Donello, et al.			
	AO	2005/0101582	05/2005	Lyons, et al.			
	AP	2005/0181017	08/2005	Hughes, et al.			
	AQ	2005/0232966	10/2005	Hughes, et al.			
	AR	2005/0244464	11/2005	Hughes, et al.			
	AS	2005/0244469	11/2005	Whitcup, et al.			
	AT	2005/0244474	11/2005	Huang, et al.			
	AU	2006/0009498	01/2006	Whitcup			
	AV	2006/0233857	10/2006	Whitcup, et al.			
	AW	2006/0233859	10/2006	Whitcup, et al.			
	AX	2007/0224246	09/2007	Hughes, et al.			
	AY	2007/0298073	12/2007	Whitcup, et al.			
	AZ	3,416,530	12/1968	Ness			
/S.F./	AAA	3,432,592	03/1969	Speiser			

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement          by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 440882000201	Application No. 10/671,816
	Applicant Wong			
	Filing Date 09-25-2003		Group Art Unit 1615	

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/S.F./	ABB	3,845,770	11/1974	Theeuwes, et al.			
	ACC	3,914,402	10/1975	Shell			
	ADD	3,916,899	11/1975	Theeuwes, et al.			
	AEE	3,921,632	11/1975	Bardani			
	AFF	3,961,628	06/1976	Arnold			
	AGG	4,008,864	02/1977	Torphanmar, et al.			
	AHH	4,014,334	03/1977	Theeuwes, et al.			
	ALL	4,063,064	12/1977	Saunders, et al.			
	AJJ	4,088,864	05/1978	Theeuwes, et al.			
	AKK	4,144,317	03/1979	Higuchi, et al.			
	ALL	4,180,646	12/1979	Choi, et al.			
	AMM	4,186,184	01/1980	Zaffaroni			
	ANN	4,200,098	04/1980	Ayer, et al.			
	AOO	4,201,210	05/1980	Hughes, et al.			
	APP	4,285,987	08/1981	Ayer, et al.			
	AQQ	4,300,557	11/1981	Refojo, et al.			
	ARR	4,304,765	12/1981	Shell, et al.			
	ASS	4,327,725	05/1982	Cortese, et al.			
	ATT	4,402,979	09/1983	Shen, et al.			
	AUU	4,451,254	05/1984	Dinius, et al.			
	AVV	4,474,451	10/1984	Mizokami			
	AWW	4,478,818	10/1984	Shell, et al.			
	AXX	4,494,274	01/1985	Thurlow			
	YYY	4,521,210	06/1985	Wong			
	AZZ	4,599,353	07/1986	Bito			
	AAAA	4,668,506	05/1987	Bawa			
/S.F./	ABBB	4,756,911	07/1988	Drost, et al.			

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement          by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 440882000201	Application No. 10/671,816
	Applicant Wong			
	Filing Date 09-25-2003		Group Art Unit 1615	

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/S.F./	ACCC	4,801,460	01/1989	Goertz, et al.			
	ADDD	4,806,337	02/1989	Snipes, et al.			
	AEEE	4,865,846	09/1989	Kaufman			
	AFFF	4,945,089	07/1990	Clark			
	AGGG	4,959,217	09/1990	Sanders, et al.			
	AHHH	4,966,849	10/1990	Vallee, et al.			
	AIII	5,004,601	04/1991	Snipes			
	AJJJ	5,004,614	04/1991	Staniforth			
	AKKK	5,006,342	04/1991	Cleary, et al.			
	ALLL	5,019,400	05/1991	Gombotz			
	AMMM	5,028,624	07/1991	Chan, et al.			
	ANNN	5,034,413	07/1991	Chan, et al.			
	AOOO	5,075,115	12/1991	Brine			
	APPP	5,082,655	01/1992	Snipes, et al.			
	AQQQ	5,169,638	12/1992	Dennis, et al.			
	ARRR	5,268,178	12/1993	Calhoun, et al.			
	ASSS	5,314,419	03/1994	Pelling			
	ATTT	5,322,691	06/1994	Darougar, et al.			
	AUUU	5,330,992	07/1994	Eissenstat, et al.			
	AVVV	5,356,629	10/1994	Sander, et al.			
	AWWW	5,384,333	01/1995	Davis, et al.			
	AXXX	5,385,887	01/1995	Yim, et al.			
	AYYY	5,476,511	12/1995	Gwon, et al.			
	AZZZ	5,597,897	01/1997	Ron, et al.			
	AAAA	5,601,844	02/1997	Kagayama, et al.			
	BBBB	5,656,297	08/1997	Bernstein, et al.			
/S.F./	ACCCC	5,660,847	08/1997	Magruder, et al.			

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement          by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/S.F./	ADDDD	5,660,851	08/1997	Domb			
	AEEEE	5,688,819	11/1997	Woodward, et al.			
	AFFFF	5,693,335	12/1997	Xia, et al.			
	AGGGG	5,707,643	01/1998	Ogura			
	AHHHH	5,755,785	05/1998	Rowsey, et al.			
	AIIII	5,773,019	06/1998	Ashton, et al.			
	AJJJJ	5,773,021	06/1998	Gurtler, et al.			
	AKKKK	5,824,074	10/1998	Koch			
	ALLLL	5,882,682	03/1999	Rork, et al.			
	AMMMM	5,902,598	05/1999	Chen, et al.			
	ANNNN	5,941,250	08/1999	Aramant, et al.			
	AOOOO	5,962,027	10/1999	Hughes			
	APPPP	5,972,369	10/1999	Roorda, et al.			
	AQQQQ	6,045,791	04/2000	Liu			
	ARRRR	6,051,576	04/2000	Ashton, et al.			
	ASSSS	6,063,116	05/2000	Kelleher			
	ATTTT	6,074,661	06/2000	Olejnik, et al.			
	AUUUU	6,217,911	04/2001	Vaughn, et al.			
	AVVVV	6,309,669	10/2001	Setterstrom, et al.			
	AWWWW	6,329,369	12/2001	Chow, et al.			
	AXXXX	6,331,313	12/2001	Wong, et al.			
	AYYYY	6,369,116	04/2002	Wong, et al.			
	AZZZZ	6,403,649	06/2002	Woodward, et al.			
	AAAAAA	6,497,729	12/2002	Moussy, et al.			
	ABBBBB	6,534,542	03/2003	Chow, et al.			
	ACCCCC	6,537,568	03/2003	Olejnik, et al.			
/S.F./	ADDDD	6,545,182	04/2003	Chow, et al.			

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 440882000201	Application No. 10/671,816
	Applicant Wong			
	Filing Date 09-25-2003		Group Art Unit 1615	

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/S.F./	AE EEEE	6,699,493	03/2004	Wong			
↓	AFFFFF	6,713,081	03/2004	Robinson, et al.			
	AGGGGG	6,726,918	04/2004	Wong, et al.			
	AHHHHH	6,841,684	01/2005	Chow, et al.			
	AIIIII	7,048,946	02/1999	Wong, et al.			
	AJJJJJ	7,091,232	08/2006	Chow, et al.			
	AKKKKK	7,141,597	11/2006	Chow, et al.			
	ALLLLL	7,276,522	10/2007	Heidelbaugh, et al.			
/S.F./	MMMMM	7,335,803	02/2008	Chow, et al.			

## Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/S.F./	ANNNNN	CA 1,333,770	10/1988	Canada				
↓	AOOOOO	CA 2,336,703	01/2000	Canada				
	APPPPP	EP 0 052 916	07/1981	Europe				
	AQQQQQ	EP 0 102 265	03/1984	Europe				
	ARRRRR	EP 0 197 718	03/1986	Europe			X	
	ASSSSS	EP 0 311 065	10/1998	Europe				
	ATTTTT	EP 0 322 319	06/1989	Europe				
	AUUUUU	EP 0 364 417	09/1989	Europe				
	AVVVVV	EP 0 474 098	03/1992	Europe				
	AWWWWW	EP 0 992 244	04/2000	Europe				
	AXXXXX	WO 1991/15495	10/1991	PCT				
	AYYYYY	WO 1991/18940	12/1991	PCT			X	
	AZZZZZ	WO 1992/21660	12/1992	PCT				
	AAAAAA	WO 1993/10141	05/1993	PCT			X	
/S.F./	ABBBBB	WO 1994/03427	02/1994	PCT				

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement          by Applicant</b> (Use several sheets if necessary)  (37 CFR § 1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
	Applicant Wong		
	Filing Date 09-25-2003	Group Art Unit 1615	

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/S.F./	ACCCCCC	WO 1994/18956	09/1994	PCT				
	ADDDDDD	WO 1994/10202	05/1994	PCT				
	AEEEEEE	WO 1994/14808	07/1994	PCT				
	AFFFFFF	WO 1996/38174	12/1996	PCT			X	
	AGGGGGG	WO 1997/26869	07/1997	PCT			X	
	AHHHHHH	WO 1998/22130	05/1998	PCT				
	AIIIIII	WO 2000/02564	01/2000	PCT			X	
	AJJJJJJ	WO 2000/62760	10/2000	PCT				
	AKKKKKK	WO 2000/56340	09/2000	PCT			X	
	ALLLLLL	WO 2001/30323	05/2001	PCT				
	AMMMMMM	WO 2002/02076	01/2002	PCT				
	ANNNNNN	WO 2002/43785	06/2002	PCT			X	
	AOOOOOO	WO 2003/094888	05/2003	PCT			X	
	APPPPPP	WO 2004/026106	09/2003	PCT			X	
	AQQQQQQ	WO 2004/062649	07/2004	PCT			X	
	ARRRRRR	WO 2005/110362	04/2005	PCT			X	
	ASSSSSS	WO 2006/093758	09/2006	PCT			X	
/S.F./	ATTTTTT	WO 2007/130945	11/2007	PCT			X	

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/S.F./	AUUUUUU	Aguilar, H.E., et al. "Vancomycin Levels After Intravitreal Injection," <i>Retina</i> , 1995; 15:428-432.
	AVVVVVV	Ahmad, M., et al. "Ortho Ester Hydrolysis: Direct Evidence for a Three-Stage Reaction Mechanism," <i>Journal of American Chemistry</i> , 1979; 101(10):2669-2677.
	AWWWWWW	Ahmed, I., et al. "Macular disorders: cystoid macular edema," <i>Ophthalmology</i> , Yanoff, M., Duker, J.S., eds. London: Mosby, 1999; 34.1-34.6.
/S.F./	AXXXXXX	Akduhan, L., et al. "The early treatment diabetic retinopathy study," <i>Clinical trials in ophthalmology: a summary and practice guide</i> , Kertes, P.S., Conway, M.D., eds. Baltimore: Williams & Wilkins, 1998; 15-35.

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/S.F./	AYYYYYY	Algvere, P.V., et al. "Transplantation of RPE in Age-Related Macular Degeneration: Observations in Disciform Lesions and Dry RPE Atrophy," <i>Graefes Archives of Clinical Experimental Ophthalmology</i> , 1997; 235(3):149-158.
	AZZZZZ	Anderson, L.C., et al. "An Injectable Substained Release Fertility Control System," <i>Contraception</i> , 1976; 13:375-384.
	AAAAAAA	Andreau, K., et al. "Induction of apoptosis by dexamethasone in the B cell lineage," <i>Immunopharmacology</i> , 1998 Jul; 40(1):67-76.
	ABBBBBB	Antcliff, R., et al. "The pathogenesis of edema in diabetic maculopathy," <i>Seminars in Ophthalmology</i> , 1999; 14:223-232.
	ACCCCCC	Araie, M. and Maurice, D.M. "The Loss of Fluorescein, Fluorescein Glucuronide and Fluorescein Isothiocyanate Dextran From the Vitreous by the anterior and Retinal Pathways," <i>Experimental Eye Research</i> , 1991; 52:27-39.
	ADDDDDD	Baker, R. "Monolithic Devices," <i>Controlled Release of Biologically Active Agents</i> , New York: John Wiley & Sons, 1987; 50-75.
	AEEEEEE	Barnas, U., et al. "Parameters Associated with Chronic Renal Transplant Failure," <i>Nephrology Dialysis Transplantation</i> , 1997; 12(Suppl 2):82-85.
	AFFFFFF	Barza, M., et al. "Pharmacokinetics of Intravitreal Carbenicillin, Cefazolin, and Gentamicin in Rhesus Monkeys," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1983; 24:1602-1606.
	AGGGGGG	Beck, R.W., et al. "The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple Sclerosis," <i>New England Journal of Medicine</i> , 1993; 329(24):1764-1769.
	AHHHHHH	Beck, R.W., et al. "A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis," <i>New England Journal of Medicine</i> , 1992 Feb 27; 326(9):634-5.
	AIIIIII	Bennett, W.M. and Barry, J.M. "Failure of Dexamethasone to Provide Adequate Chronic Immunosuppression for Renal Transplantation," <i>Transplantation</i> , 1979; 27(3):218-219.
	AJJJJJJ	Ben-Nun, J., et al. "Pharmacokinetics of Intravitreal Injection," <i>Investigative Ophthalmology &amp; Visual Science</i> 1989; 30(6):1055-1061.
	AKKKKKK	Bigar, F. and C.P. Herbort. "Corneal Transplantation," <i>Current Opinion in Ophthalmology</i> , 1992; 3(4):473-481.
	ALLLLLL	Bingaman, D.P., et al. "Inhibition of preretinal neovascularization in pigs by intravitreal triamcinolone acetonide," <i>Investigative Ophthalmology and Visual Science</i> , 1995; 36(4):S401, abstract 1867.
	MMMMMMM	Bito, L.Z. "Prostaglandins and Related Compounds as Potential Ocular Therapeutic Agents," <i>Biological Protection with Prostaglandins</i> , Vol. I, Cohen, M.M. ed., Boca Raton: CRC Press Inc., 1985; 31-252.
	ANNNNNN	Bito, L.Z. "Prostaglandins, Other Eicosanoids, and their Derivatives as Potential Antiglaucoma Agents," <i>Glaucoma: Applied Pharmacology in Medical Treatment</i> , Drance, S.M. and Neufeld, A.H. Eds., New York: Grune & Stratton, 1984; 477-505.
	AOOOOOO	Bito, L.Z. "Prostaglandins: Old Concepts and New Perspectives," <i>Archives of Ophthalmology</i> , 1987; 105:1036-1039.
/S.F./	APPPPPP	Bolen, J.B. "Nonreceptor tyrosine protein kinases," <i>Oncogene</i> , 1993; 8(8):2025-2031.

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/S.F./	AQQQQQQQ	Brubaker, R.F. "Mechanism of Action of Bimatoprost (Lumigan <sup>TM</sup> )," <i>Survey of Ophthalmology</i> , 2001; 45(Suppl 4):S347-S351.
	ARRRRRRR	Budavari, S., et al. eds. <i>The Merck Index</i> , 12 <sup>th</sup> ed. Rahway, NJ: Merck and Co., 1996; Table of Contents only.
	ASSSSSSS	Bundgaard, H. and Moss, J. "Prodrugs of Peptides IV: Bioreversible Derivatization of the Pyroglutamyl Group by N-Acylation and N-Aminomethylation to Effect Protection against Pyroglutamyl Aminopeptidase," <i>Journal of Pharmaceutical Sciences</i> , 1989; 78(2):122-126.
	ATTTTTTT	Burdon, M.A. and P. McDonnell. "A Survey of Corneal Graft Practice in the United Kingdom," <i>Eye</i> , 1995; 9(Suppl):6-12.
	AUUUUUUU	Chacko, D.M., et al. "Survival and Differentiation of Cultured Retinal Progenitors Transplanted in the Subretinal Space of the Rat," <i>Biochemical and Biophysical Research Communications</i> , 2000; 268(3):842-846.
	AVVVVVVV	Challa, J.K., et al. "Exudative Macular Degeneration and Intravitreal Triamcinolone: 18 month follow up," <i>Australian and New Zealand Journal of Ophthalmology</i> , 1998; 26:277-281.
	WWWWWWW	Chang, David, et al. "Phase II results of an intraocular steroid delivery system for cataract surgery," <i>Ophthalmology</i> , 1996 June; 106(6):1172-1177.
	AXXXXXXX	Chang, M., et al. "Basic Science and Clinical Aspects of Wound Healing in Glaucoma Filtering Surgery," <i>Journal of Ocular Pharmacology and Therapeutics</i> , 1998; 14(1):75-95.
	AYYYYYYY	Charles, J., et al. "Use of Bioerodible Polymers Impregnated with Mitomycin in Glaucoma Filtration Surgery in Rabbits," <i>Ophthalmology</i> , 1991 Apr; 98(4):503-508.
	AZZZZZZZ	Chen, J., et al. "Lumigan®: A Novel Drug for Glaucoma Therapy," <i>Optometry in Practice</i> , 2002; 3:95-102.
	AAAAAAAA	Clarkson, J.G. "Central retinal vein occlusion," <i>Retina</i> , 3 <sup>rd</sup> ed. Ryan, S., Schachar, A.P., eds. St. Louis, MO: CV Mosby; 2001; 1368-1375.
	BBBBBBBB	Coleman, A.L., et al. "A 3-Month Randomized Controlled Trial of Bimatoprost (LUMIGAN) Versus Combined Timolol and Dorzolamide (Cosopt) in Patients with Glaucoma or Ocular Hypertension," <i>Ophthalmology</i> , 2003; 110(12):2362-2368.
	ACCCCCCC	Cuff, G. and Raouf, F. "A Preliminary Evaluation of Injection Molding as a Technology to Produce Tablets," <i>Pharmaceutical Technology</i> , 1998; 96-106.
	DDDDDDDD	Davis, P.A., et al. "Intraocular Implant For Controlled 5-Fluorouracil Release," <i>Proceedings of the 19th International Symposium of Controlled Release Bioactive Materials</i> , 1992; 19:339-340.
	EEEEEEEE	Di Colo, G. "Controlled Drug Release From Implantable Matrices Based On Hydrophobic Polymers," <i>Biomaterials</i> , 1992; 13(12):850-856.
	AFFFFFFF	Dick, J., et al. "Macular edema," <i>Retina</i> , 3 <sup>rd</sup> ed. Ryan, S., Schachar, A.P., eds. St. Louis, MO: CV Mosby; 2001; 967-979.
/S.F./	GGGGGGGG	Dinning, W.J. "Intermediate Uveitis: history, terminology definition pars planitis: systemic disease associations," <i>Developments in Ophthalmology: Intermediate Uveitis</i> , W.R.F. Böke, et al. eds. Basel: Karger, 1992; 3-8.

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

## Information Disclosure Statement

by Applicant

(Use several sheets if necessary)

(37 CFR §1.98(b))

## Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/S.F./	HHHHHHHH	Druilhe, A., et al. "Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action," <i>Apoptosis</i> , 2003 Oct; 8(5):481-95.
	IIIIIIII	<i>Encyclopedia of Polymer Science and Technology</i> , vol. 3. New York: Interscience Publishers, Inc., 2003; Table of Contents only, v.
	JJJJJJJJ	Enzmann, V., et al. "Immunological Problems of Transplantation into the Subretinal Space," <i>Acta Anatomica</i> , 1998; 162(2-3):178-183.
	KKKKKKKK	Fatt, I. "Flow and Diffusion In the Vitreous Body of The Eye," <i>Bulletin of Mathematical Biology</i> , 1975; 37:85-90.
	LLLLLLLL	Fekrat, S. and Finkelstein, D. "The Central Vein Occlusion Study," <i>Clinical trials in ophthalmology: a summary and practice guide</i> , Kertes, P.S., Conway, M.D., eds. Baltimore, MD: Williams & Wilkins, 1998; 129-143.
	MMMMMMMM	Frank, R.N. "Etiologic mechanisms in diabetic retinopathy," <i>Retina</i> , 3 <sup>rd</sup> ed. Ryan, S., Schachat, A.P., eds. St. Louis, MO: CV Mosby; 2001; 1259-1294.
	NNNNNNNN	Friedrich, S., et al. "Finite Element Modeling of Drug Distribution in the Vitreous Humor of the Rabbit Eye," <i>Annals of Biomedical Engineering</i> , 1997; 25:303-314.
	OOOOOOOO	Gennaro, A.R. ed. <i>Remington: The Science and Practice of Pharmacy</i> , 19 <sup>th</sup> Ed. Easton, PA: Mack Publishing Company, 1995; Table of Contents only, xv-xvi.
	PPPPPPPP	Gillies, M.C., et al. "Safety of an intravitreal injection of triamcinolone," <i>Archives of Ophthalmology</i> , 2004 Mar; 122:336-340.
	QQQQQQQQ	Gilman, A.G., et al. eds. <i>Goodman and Gilman's: The Pharmacological Basis of Therapeutics</i> . 8 <sup>th</sup> Ed. New York: Pergamon Press, 1990; Table of Contents only, xi-xvi.
	RRRRRRRR	Goldberg, Ivan, "Drugs for glaucoma," <i>Australian Prescriber</i> , 2002; 25(6):142-146.
	SSSSSSSS	Goodman, L.S. and A. Gilman eds. <i>The Pharmacological Basis of Therapeutics</i> , 9 <sup>th</sup> Ed. New York: McGraw-Hill, 1996; Table of Contents only, v-xii.
	TTTTTTTT	Greenfield, R.S., et al. "Evaluation <i>in Vitro</i> of Adriamycin Immunoconjugates Synthesized Using an Acid-sensitive Hydrazone Linker," <i>Cancer Research</i> , 1990; 50:6600-6607.
	UUUUUUUU	Guan, D., et al. "The Therapeutic Window of Cyclosporine in Chinese Recipients of Renal Transplantation," <i>Transplantation Proceedings</i> , 1995; 27(1):850-851.
	VVVVVVVV	Hari, P. and Srivastava, R.N. "Pulse Corticosteroid Therapy with Methylprednisolone or Dexamethasone," <i>Indian Journal of Pediatrics</i> , 1998; 65(3):557-560.
	WWWWWWWW	Hayreh, S.S. "Posterior Drainage of the Intraocular Fluid From the Vitreous," <i>Experimental Eye Research</i> , 1996; 5:123-144.
	XXXXXXXX	Heller, J. "Biodegradable Polymers in Controlled Drug Delivery," <i>CRC Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1984; 1(1):39-90.
	YYYYYYYY	Heller, J. "Bioerodible Hydrogels," <i>Hydrogels in Medicine and Pharmacy</i> , Vol. 3: Properties and Applications, Peppas, N.A. ed. Boca Raton: CRC Press, 1987; 138-149.
	ZZZZZZZZ	Heller, J. "Poly (Ortho Esters)," <i>Biopolymers I</i> , Peppas, N.A. and R.S. Langer eds. New York: Springer-Verlag, 1993; 41-92.
/S.F./	AAAAAAAA	Heller, J., et al. "Poly(ortho ester) Biodegradable Polymer Systems," <i>Methods in Enzymology</i> , Widder, K.J. and R. Green eds. Orlando: Academic Press, Inc., 1985; 422-436.

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615
(37 CFR § 1.98(b))			

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
/S.F./	BBBBBBBBBB	Hirano, T. "Clinical Significance of Glucocorticoid Pharmacodynamics Assessed by Antilymphocyte Action in Kidney Transplantation," <i>Transplantation</i> , 1994; 57(9):1341-1348.
	CCCCCCCC	Höckel, M., et al. "Prevention of Peritoneal Adhesions in the Rat With Sustained Intraperitoneal Dexamethasone Delivered by a Novel Therapeutic System," <i>Annales Chirurgiae et Gynaecologiae</i> , 1987; 76(6):306-313.
	DDDDDDDD	Inoue, M., et al. "Vitreous Concentrations of Triamcinolone Acetonide in Human Eyes After Intravitreal or Subtenon Injection," <i>American Journal of Ophthalmology</i> , 2004; 138(6):1046-8.
	EEEEEEEE	Jackanicz, T., et al. "Polyactic Acid As a Biodegradable Carrier for Contraceptive Steroids" <i>Contraception</i> , 1973; 8(3):227-234.
	FFFFFFF	Jaffe, G.J., et al. "Safety and Pharmacokinetics of an Intravitreal Fluocinolone Acetonide Sustained Delivery Device," <i>Investigative Ophthalmology &amp; Visual Science</i> , 2000; 41(11):3569-3575.
	GGGGGGGG	Jaffe, G.J., et al. "Safety, Efficacy, and Pharmacokinetics of an Intravitreal Fluocinolone Sustained Drug Delivered System," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1999; 40(4):S988, abstract 5195.
	HHHHHHHH	Jampel, H., et al. "Glaucoma Filtration Surgery in Monkeys Using 5-Fluorouridine in Polyanhydride Disks," <i>Archives of Ophthalmology</i> , 1990 Mar; 108(3):430-435.
	IIIIIIII	Jay, W.M., et al. "Intravitreal Cefazidime in a Rabbit Model: Dose-and Time-Dependent Toxicity and Pharmacokinetic Analysis," <i>Journal of Ocular Pharmacology</i> , 1987; 3(3):257-262.
	JJJJJJJJ	Jellinek, D., et al. "Inhibition of Receptor binding by High-affinity RNA Ligands to Vascular Endothelial Growth Factor," <i>Biochemistry</i> , 1994; 33:10450-56.
	KKKKKKKK	Jennings, T., et al. "Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema," <i>Japanese Journal of Ophthalmology</i> , 1988; 32(4):385-391.
	LLLLLLLL	Jeong, J.H., et al. "Novel Intracellular Delivery System of Antisense Oligonucleotide by Self-Assembled Hybrid Micelles Composed of DNA/PEG Conjugate and Cationic Fusogenic Peptide," <i>Bioconjugate Chemistry</i> , 2003; 14:473-479.
	MMMMMMMM	Johnson, F. and Maurice, D. "A Simple Method of Measuring Aqueous Humor Flow With Intravitreal Fluoresceinated Dextran," <i>Experimental Eye Research</i> , 1984; 39:791-805.
	NNNNNNNN	Jonas, J.B., et al. "Intraocular pressure after intravitreal injection of triamcinolone acetonide," <i>British Journal of Ophthalmology</i> , 2003; 87:24-27.
	OOOOOOOO	Kane, A., et al. "Intravitreal Injection of Gentamicin in Rabbits," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1981; 20(5):593-597.
	PPPPPPPP	Kang, S.W., et al. "Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema," <i>Archives of Ophthalmology</i> , 2006 May; 124(5):653-8.
	QQQQQQQQ	Kendall, R.L. and K.A. Thomas. "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <i>Proceedings of the National Academy of Science USA</i> , 1994; 90:10705-09.
/S.F./	RRRRRRRR	Kher, V., et al. "Low-Dose Dexamethasone- An Alternative Therapy for Acute Renal Allograft Rejection," <i>Transplantation Proceedings</i> , 1992; 24(5):1725.

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
/S.F./	ASSSSSSSS	Kim, K.J., et al. "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <i>Nature</i> , 1993; 362(6423):841-844.
	TTTTTTTTT	Kimura, H. and Ogura, Y. "Biodegradable Polymers for Ocular Drug Delivery," <i>Ophthalmologica</i> , 2001; 215:143-155.
	JUUUUUUUU	Kinsella, J.L., et al. "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <i>Experimental Cell Research</i> , 1992; 199:56-62.
	VVVVVVVVV	Kochinke, F. and Wong, V.G. "Biodegradable Drug Delivery System for Uveitis Treatment, Oculex Pharmaceuticals, Inc.," Slide Presentation, 1996; total pages 20.
	VWWWWW	Kralinger, M.T., et al. "Slow Release of Acetylsalicylic Acid by Intravitreal Silicone Oil," <i>Retina: The Journal of Retinal and Vitreous Diseases</i> , 2001; 21(5):513-520.
	XXXXXXXXX	Kunou, Noriyuki, et al. "Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate," <i>Journal of Biomedical Materials Research</i> , 2000; 51(4):635-641.
	AYYYYYYYYY	Laurent, U.B.G. and Fraser, J.R.E. "Turnover of Hyaluronate in the Aqueous Humor And Vitreous Body of the Rabbit," <i>Experimental Eye Research</i> , 1983; 36:493-504.
	ZZZZZZZZZ	Lee, D., et al. "Complications of Subconjunctival 5-Fluorouracil Following Glaucoma Filtering Surgery," <i>Ophthalmic Surgery</i> , 1987 Mar; 18(3):187-190.
	AAAAAAAAA	Lee, D., et al. "Glaucoma Filtration Surgery in Rabbits Using Bioerodible Polymers and 5-Fluorouracil," <i>Ophthalmology</i> , 1987 Dec; 94(12):1523-1530.
	BBBBBBBBB	Lee, D., et al. "The Use of Bioerodible Polymers and 5-Fluorouracil in Glaucoma Filtration Surgery," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1988 Nov; 29(11):1692-1697.
	CCCCCCCCC	Lee, K.Y. and Wong, V.G. "Dexamethasone Posterior Segment Drug Delivery System for Treatment of Severe Uveitis," <i>American Uveitis Society</i> , 1999; Abstract.
	DDDDDDDDD	Leopold, I.H. "Nonsteroidal and steroidal anti-inflammatory agents," <i>Surgical pharmacology of the Eye</i> , Sears, M., Tarkkanen, A., eds. New York: Raven Press, 1985; 83-133.
	EEEEEEEEEEE	Marcon, I. "A double-masked comparison of betaxolol and levobunolol for the treatment of primary open-angle glaucoma," <i>Arquivos Brasileiros de Oftalmologia</i> , 1990; 53(1):27-32.
	FFFFFFFFFFF	Mariani, M., et al. "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <i>Proceedings of the American Association for Cancer Research</i> , 1994; 35:381, abstract 2268.
	GGGGGGGGG	Mathebulu, S.D. "A Review of Pharmacological Therapy for Glaucoma," <i>The South African Optometrist</i> , 2005 Sept; 64(3):89-96.
	AHHHHHHHHH	Maurice, D.M. "The Exchange of Sodium Between The Vitreous Body and The Blood And Aqueous Humour," <i>Journal of Physiology</i> , 1957; 137:110-125.
	IIIIIIIIII	Maurice, D.M. "Flow of Water Between Aqueous and Vitreous Compartments in the Rabbit Eye," <i>American Journal of Physiology</i> , 1987; 252 (1):F104-F108.
/S.F./	AJJJJJJJJJ	Maurice, D.M. and Mishima, S. "Ocular Pharmacokinetics," <i>Pharmacology of the Eye</i> , M.L. Sears ed. New York: Springer-Verlag, 1984; 19-116.

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

**Information Disclosure Statement  
by Applicant**  
(Use several sheets if necessary)

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/S.F./	KKKKKKKKK	Meadows, D.L., et al. "Ocular Drug Delivery with Subconjunctival Implants," <i>Proceedings of the International Symposium on Controlled Release of Bioactive Materials</i> , Controlled Release Society, Inc., 1994; 21:593-594.
	ALLLLLLLLLL	Migita, K., et al. "Apoptosis Induction in Human Peripheral Blood T Lymphocytes by High-Dose Steroid Therapy", <i>Transplantation</i> , 1997; 63(4):583-587.
	MMMMMM	Miller, R., et al. "Degradation Rates of Oral Resorbable Implants (Polyactates and Polyglycolates): Rate Modification with Changes in PLA/PGA Copolymer Ratios," <i>Journal of Biomedical Materials Research</i> , 1977; 11(5):711-719.
	ANNNNNNNNN	Mittal, R., et al. "Treatment of Acute Rejection in Live Related Renal Allograft Recipients: A Comparison of Three Different Protocols," <i>Nephron</i> , 1977; 77(2):186-189.
	AOOOOOOOOO	Molfino, F., et al. "IOP-lowering effect of dorzolamide 2% versus brimonidine tartrate 0.2%. A prospective randomized cross over study," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1998 Mar; 39(4):S481.
	PPPPPPPPPP	Morita, Y., et al. "Polymer Blend Implant for Ocular Delivery of Fluorometholone," <i>Biological &amp; Pharmaceutical Bulletin</i> , 1998; 21(1):72-75.
	QQQQQQQQQ	Moseley, H., et al. "Routes of Clearance of Radioactive Water From The Rabbit Vitreous," <i>British Journal of Ophthalmology</i> , 1984; 68:145-151.
	RRRRRRRRRR	Nauck, M., et al. "Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells," <i>European Journal of Pharmacology</i> , 1998; 341:309-315.
	SSSSSSSSSS	Nauck, M., et al. "Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids," <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1997; 16:398-406.
	TTTTTTTTTT	Nilsson, S.F.E., et al. "PGF2 Increases Uveoscleral Outflow," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1987; 28(3):284, abstract 9.
	UUUUUUUUU	Ohtori, A. and Tojo, K. "In vivo/in Vitro Correlation of Intravitreal Delivery of Drugs With the Help of Computer Simulation," <i>Biological &amp; Pharmaceutical Bulletin</i> , 1994; 17(2):283-290.
	VVVVVVVVV	Oplinger, N.L., et al. "A Comparison of Corneal Autografts With Homografts," <i>Ophthalmic Surgery and Lasers</i> , 1998; 29(4):305-308.
	WWWWWWW	Orth, D. "The branch vein occlusion study," <i>Clinical trials in ophthalmology: A summary and practice guide</i> , Kertes, P, and Conway, M, eds., Baltimore, MD: Williams & Wilkins, 1998; 113-127.
	XXXXXXXXXX	Patel, N.P., et al. "Indications for and Outcomes of Repeat Penetrating Keratoplasty, 1989-1995," <i>Ophthalmology</i> , 2000; 107(4):719-724.
	YYYYYYYYY	Pearson, P.A., et al. "Clearance and Distribution of Ciprofloxacin After Intravitreal Injection," <i>Retina</i> , 1993; 13:326-330.
	ZZZZZZZZZ	Pe'er, J., et al. "Vascular endothelial growth factor by platelet-activating factor upregulation in human central retinal vein occlusion," <i>Ophthalmology</i> , 1998; 105:412-416.
/S.F./	AAAAAAAAA	Peyman, G.A. and Herbst, R. "Bacterial endophthalmitis," <i>Archives of Ophthalmology</i> , 1974; 91(5):416-418.

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

**Information Disclosure Statement  
by Applicant**  
(Use several sheets if necessary)

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/S.F./	BBBBBBBBBB	Peyman, G.A., et al. "A Technique for Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration Secondary to Extensive Subfoveal Scarring," <i>Ophthalmic Surgery</i> , 1991; 22(2):102-108.
	CCCCCCCCC	Pinar, V. "Intermediate Uveitis," <i>Massachusetts Eye &amp; Ear Infirmary Immunology Service</i> , Boston.
	DDDDDDDDDD	Plowman, G.D., et al. "Receptor Tyrosine Kinases as Targets for Drug Intervention," <i>Drug News &amp; Perspectives</i> , 1994; 7(6): 334-339.
	EEEEEEEEEE	Rahil, J., et al. "Reactivity and Mechanism of Hydrolysis of Phosphonamides," <i>Journal of the American Chemical Society</i> , 1981; 103:1723-1734.
	FFFFFFFFFFFF	Rao, K.V., et al. "Successful Renal Transplantation in a Patient With Anaphylactic Reaction to Solu-Medrol (Methylprednisolone Sodium Succinate)," <i>American Journal of Medicine</i> , 1982; 72(1):161-163.
	GGGGGGGGGG	Riordan-Eva, P., et al. "Orbital floor steroid injections in the treatment of uveitis," <i>Eye</i> , 1994; 8(1):66-69.
	HHHHHHHHHH	Robin, Jeffrey B., et al. "The Histopathology of Corneal Neovascularization," <i>Archives of Ophthalmology</i> , 1985; 103(2):284-287.
	IIIIIIIIII	Roff, W.J. and Scott, J.R. eds. <i>Handbook of Common Polymers</i> , Cleveland: CRC Press, 1971; Table of Contents.
	JJJJJJJJJJ	Rootman, D.S., et al. "Toxicity and Pharmacokinetics of Intravitreally Injection Ciprofloxacin in Rabbit Eyes," <i>Canadian Journal of Ophthalmology</i> , 1992; 27(6):277-282.
	KKKKKKKKKK	Sasaki, H., et al. "Drug Absorption Behavior After Periocular Injections," <i>Biological &amp; Pharmaceutical Bulletin</i> , 1999; 22(9):956-960.
	LLLLLLLLLL	Schimmer B.P. and Parker K.L. "Adrenocorticotrophic hormone; Adrenocortical Steroids and their Synthetic Analogs; Inhibitors of the Synthesis and Actions of Adrenocortical Hormones," <i>The Pharmacological Basis of Therapeutics 10<sup>th</sup> ed.</i> , Hardman, J.G. and Limbard, L.L. eds, New York: McGraw-Hill, 2001; 1649-1677.
	MMMMMMMM	Schindler, R.H., et al. "The Clearance of Intravitreal Triamcinolone Acetonide," <i>American Journal of Ophthalmology</i> , 1982; 93(4):415-417.
	NNNNNNNNNN	Scholes, G.N., et al. "Clearance of Triamcinolone From Vitreous," <i>Archives of Ophthalmology</i> , 1985; 103(10):1567-1569.
	OOOOOOOOOO	Scott, J.R. and W.J. Roff eds. "Permeability," <i>Handbook of Common Polymers</i> , Cleveland: CRC Press, 1971; 554-558.
	PPPPPPPPPP	Shields, Bruce M. "Glaucoma Filtering Procedures," <i>A Study Guide for Glaucoma</i> , Baltimore: Williams & Wilkins, 1982; 453-476.
	QQQQQQQQQQ	Siebold, et al. <i>Prodrug</i> , 1989; 5:3.
	RRRRRRRRRR	Smith, T., et al. "Sustained-release subconjunctival 5-Fluorouracil," <i>Ophthalmic Surgery and Lasers</i> , 1996 Sept; 27(9):763-767.
	SSSSSSSSSS	Starr, M.S. "Further Studies on the Effect of Prostaglandin on Intraocular Pressure in the Rabbit," <i>Experimental Eye Research</i> , 1971; 11(2):170-177.
/S.F./	TTTTTTTTTT	Stewart, W., et al. "Washout periods for brimonidine 0.2% and latanoprost 0.005%," <i>American Journal of Ophthalmology</i> , 2001 June; 131(6):798-799.

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement          by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 440882000201	Application No. 10/671,816
		Applicant Wong	
		Filing Date 09-25-2003	Group Art Unit 1615

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
/S.F./	UUUUUUUUUU	Taba, K.E., et al. "Intravitreal sustained release fluocinolone implant inhibits experimental choroidal neovascularization," <i>Investigative Ophthalmology &amp; Visual Science</i> , 1999 Mar; 40(4):S172, abstract 920.
	VVVVVVVVVV	Takano, S., et al. "Inhibition of Angiogenesis by a Novel Diaminoanthraquinone that Inhibits Protein Kinase C," <i>Molecular Biology of the Cell</i> , 1993; 4:358A, abstract 2076.
	VVVVVVVVVV	Tan, D.T.H., et al. "Randomized Clinical Trial of a New Dexamethasone Delivery System (Surodex) for Treating Post-Cataract Surgery Inflammation," <i>Ophthalmology</i> , 1999; 106(2):223-231.
	XXXXXXXXXX	Tennant, J.L. "Cystoid maculopathy," <u>Current concepts in cataract surgery: selected proceedings of the fifth biennial cataract surgical congress</u> , Emery, J.M. ed. St. Louis: CV Mosby, 1978; 360-362.
	YYYYYYYYYY	Theng, J.T.S., et al. "Pharmacokinetic and Toxicity Study of an Intraocular Cyclosporine DDS in the Anterior Segment of Rabbit Eyes," <i>Investigative Ophthalmology &amp; Visual Science</i> , 2003 Nov; 44(11):4895-4899.
	ZZZZZZZZZZ	Tsubota, K. "Ocular Surface Management in Corneal Transplantation, A Review," <i>Japanese Journal of Ophthalmology</i> , 1999; 43(6):502-508.
	AAAAAAAAAA	Turcotte, J.G., et al. "Rejection Crises in Human Renal Transplant Recipients: Control with High Dose Methylprednisolone Therapy," <i>Archives of Surgery</i> , 1972; 105(1):230-236.
	BBBBBBBBBB	<u>The United States Pharmacopeia, The National Formulary</u> , "USP 24/NF 19," 2000; 1941-1951.
	CCCCCCCCCC	Watson, P., et al. "A Six-month, Randomized, Double-masked Study Comparing Latanoprost with Timolol in Open-angle Glaucoma and Ocular Hypertension," <i>Ophthalmology</i> , 1996; 103(1):126-137.
	DDDDDDDD	Weisbecker, C.A., et al., eds. <u>Physicians' Desk Reference for Ophthalmology 27<sup>th</sup> ed.</u> , Montvale, NJ: Medical Economics Company, 1998; 7-8, 278-279.
	EEEEEEEEEE	Wingate, R.J., et al. "Intravitreal Triamcinolone and Elevated Intraocular Pressure," <i>Australian and New Zealand Journal of Ophthalmology</i> , 1999 Dec; 27(6):431-2.
	FFFFFFF	Woodward, D.F., et al. "AGN 192024 (Lumigan®): A Synthetic Prostanoid Analog that Lowers Primate Intraocular Pressure by Virtue of Its Inherent Pharmacological Activity," <i>Investigative Ophthalmology &amp; Visual Science</i> , 2002; 43, abstract 4110.
	GGGGGGGGG	Woodward, D.F., et al. "The Pharmacology of Bimatoprost (Lumigan™)," <i>Survey of Ophthalmology</i> , 2001; 45(Suppl 4):S337-S345.
	HHHHHHHHH	Wright, P.S., et al. "Inhibition of Angiogenesis In Vitro and In Ovo with an Inhibitor of Cellular Protein Kinases, MDL 27032," <i>Journal of Cellular Physiology</i> , 1992; 152(3):448-457.
/S.F./	IIIIIIIIII	Xu, J., et al. "Permeability and Diffusion in Vitreous Humor: Implications for Drug Delivery," <i>Pharmaceutical Research</i> , 2000; 17(6):664-669.

Examiner Signature /Shanon Foley/	Date Considered 06/20/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	